Table 2.
Utilization of Anticancer Medications in Neoadjuvant and Adjuvant Settings.
| Anticancer therapy | Agent | Patient count | Percentage | Anticancer therapy | Agent | Patient count | Percentage |
|---|---|---|---|---|---|---|---|
| Neoadjuvant Setting | Adjuvant setting | ||||||
| Chemotherapy | Docetaxel | 43 | 21% | Chemotherapy | Cyclophosphamide | 20 | 13% |
| Cyclophosphamide | 39 | 19% | Docetaxel | 16 | 10% | ||
| Epirubicin | 37 | 18% | Fluorouracil | 14 | 9% | ||
| Fluorouracil | 37 | 18% | Epirubicin | 13 | 8% | ||
| Carboplatin | 2 | 1% | Doxorubicin | 3 | 2% | ||
| Doxorubicin | 2 | 1% | Cisplatin | 2 | 1% | ||
| Paclitaxel | 2 | 1% | Vinorelbine | 2 | 1% | ||
| Capecitabine | 1 | 0% | |||||
| Cisplatin | 1 | 0% | |||||
| Vinorelbine | 1 | 0% | |||||
| Hormonal therapy | Letrozole | 10 | 5% | Hormonal therapy | Letrozole | 26 | 17% |
| Tamoxifen | 7 | 3% | Tamoxifen | 22 | 14% | ||
| Fulvestrant | 4 | 2% | Fulvestrant | 1 | 1% | ||
| Goserelin | 1 | 0% | Goserelin | 1 | 1% | ||
| Trastuzumab | 20 | 10% | |||||
| Targeted therapy | Pertuzumab | 1 | 0% | Targeted therapy | Trastuzumab | 16 | 10% |
| Bevacizumab | 1 | 0% | |||||